Yago Nieto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Team reports on synergistic cytotoxicity of HDAC and PARP inhibitors and decitabine in pancreatic cancer cells

A new research paper titled "Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy" has been published in Oncotarget.

United statesYago nietoApostoliam tsimberidouBorjes anderssonAbhijit chakrabortyBenignoc valdezClarkr andersenMehmeta baysalUniversity of texas md anderson cancer centerBin yuanCancer center

ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells

A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells."

United statesBorjes anderssonUday popatBenignoc valdezYago nietoDavid murrayJeremyl ramdialUniversity of texas md anderson cancer centerUniversity of albertaBin yuanCancer centerAcute myeloid leukemiaMyeloid leukemia

ABT199/Venetoclax Boosts Thiotepa s Impact on AML Cells

ABT199/Venetoclax Boosts Thiotepa s Impact on AML Cells
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesUday popatBenignoc valdezBorjes anderssonYago nietoDavid murrayJeremyl ramdialUniversity of texas md anderson cancer centerUniversity of albertaOncotarget volumeBin yuanCancer center

ABT199/Venetoclax synergism with thiotepa in acute myeloid leukemia (AML) cells

ABT199/Venetoclax synergism with thiotepa in acute myeloid leukemia (AML) cells
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesDavid murrayUday popatBenignoc valdezBorjes anderssonJeremyl ramdialYago nietoUniversity of texas md anderson cancer centerUniversity of albertaBin yuanCancer center

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoNew yorkBaden wübergYago nietoAndreas harstrickArtiva alloMary beth sandinAlexander fudukidisUniversity of texas md anderson cancer centerAmerican society of hematologyAnnounces updated phaseAre double refractoryBrentuximab vedotinCheckpoint inhibitorsAmerican society